Tag: RadioMedix
Detectnet (copper Cu 64 dotatate injection) Now Included in NCCN Guidelines® for Neuroendocrine Tumors
The newest FDA-approved PET imaging agent for neuroendocrine tumors — DetectnetTM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine…
READ MORE
Dr. Ebrahim Delpassand to be Featured Guest for CCF’s Luncheon with the Experts
Ebrahim S. Delpassand, MD, FACNM, Chairman and Medical Director at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas and founder, Chairman of the Board, and CEO of Radiomedix in Houston, will be the featured guest for Luncheon with the…
READ MORE
9 More News Items for the Carcinoid and Neuroendocrine Cancer Community
Carcinoid/neuroendocrine cancer specialist Dr. Eric Liu will be joining the Rocky Mountain Cancer Centers in Denver, Colorado, effective June 1, 2015. He and medical oncologist Dr. Allen Cohn, also from Rocky Mountain Cancer Centers, will head up …
READ MORE
Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients
For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in the United States, Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, in collaboration with…
READ MORE
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
